Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells

The interaction with platelets is of crucial importance for tumor cells passing through hematogenous metastasis. Platelets protect cancer cells from immune surveillance and exhibit many other prometastatic effects. Notably, platelets can change the epithelial tumor phenotype, a process termed epithe...

Full description

Bibliographic Details
Main Authors: Jan Moritz Ponert, Lukas Maria Gockel, Svenja Henze, Martin Schlesinger
Format: Article
Language:English
Published: MDPI AG 2018-10-01
Series:Molecules
Subjects:
EMT
Online Access:http://www.mdpi.com/1420-3049/23/10/2690
id doaj-f813b550d3214f0cb95b548f45a0fd3b
record_format Article
spelling doaj-f813b550d3214f0cb95b548f45a0fd3b2020-11-24T21:07:28ZengMDPI AGMolecules1420-30492018-10-012310269010.3390/molecules23102690molecules23102690Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer CellsJan Moritz Ponert0Lukas Maria Gockel1Svenja Henze2Martin Schlesinger3Department of Pharmacy, University of Bonn, An der Immenburg 4, 53121 Bonn, GermanyDepartment of Pharmacy, University of Bonn, An der Immenburg 4, 53121 Bonn, GermanyDepartment of Pharmacy, University of Bonn, An der Immenburg 4, 53121 Bonn, GermanyDepartment of Pharmacy, University of Bonn, An der Immenburg 4, 53121 Bonn, GermanyThe interaction with platelets is of crucial importance for tumor cells passing through hematogenous metastasis. Platelets protect cancer cells from immune surveillance and exhibit many other prometastatic effects. Notably, platelets can change the epithelial tumor phenotype, a process termed epithelial-mesenchymal transition (EMT), which confers stem cell-like properties onto tumor cells associated with an increased motility and drug resistance. The aim of the study is to investigate the impact of heparin on the platelet induced EMT program in pancreatic and prostate tumor cells. Platelet activation and interaction with cancer cells were determined by static adhesion assays. Applying ELISAs, the platelet release of EMT inducing mediators was quantified. EMT marker protein expression by tumor cells was explored by western blot and qPCR. Our data show that different tumor cell entities have different platelet binding capacities and also that a weak interaction is sufficient to change tumor cell phenotype. Additionally, unfractionated heparin (UFH) as well as low molecular weight heparin (LMWH) reduced tumor cell platelet interaction. Subsequently, attenuated platelet-derived mediator release resulted in reduced EMT marker protein and transcription factor expression by the cancer cells and decreased cell migration. These data suggest that heparin reduces platelet induced EMT program and prevents the formation of cancer cells with stem cell-like properties. This additional mechanism argues for the use of heparin in oncological applications.http://www.mdpi.com/1420-3049/23/10/2690heparinplatelettumorepithelial-mesenchymal transitionEMTcancer stem cellsenoxaparin
collection DOAJ
language English
format Article
sources DOAJ
author Jan Moritz Ponert
Lukas Maria Gockel
Svenja Henze
Martin Schlesinger
spellingShingle Jan Moritz Ponert
Lukas Maria Gockel
Svenja Henze
Martin Schlesinger
Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells
Molecules
heparin
platelet
tumor
epithelial-mesenchymal transition
EMT
cancer stem cells
enoxaparin
author_facet Jan Moritz Ponert
Lukas Maria Gockel
Svenja Henze
Martin Schlesinger
author_sort Jan Moritz Ponert
title Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells
title_short Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells
title_full Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells
title_fullStr Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells
title_full_unstemmed Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells
title_sort unfractionated and low molecular weight heparin reduce platelet induced epithelial-mesenchymal transition in pancreatic and prostate cancer cells
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2018-10-01
description The interaction with platelets is of crucial importance for tumor cells passing through hematogenous metastasis. Platelets protect cancer cells from immune surveillance and exhibit many other prometastatic effects. Notably, platelets can change the epithelial tumor phenotype, a process termed epithelial-mesenchymal transition (EMT), which confers stem cell-like properties onto tumor cells associated with an increased motility and drug resistance. The aim of the study is to investigate the impact of heparin on the platelet induced EMT program in pancreatic and prostate tumor cells. Platelet activation and interaction with cancer cells were determined by static adhesion assays. Applying ELISAs, the platelet release of EMT inducing mediators was quantified. EMT marker protein expression by tumor cells was explored by western blot and qPCR. Our data show that different tumor cell entities have different platelet binding capacities and also that a weak interaction is sufficient to change tumor cell phenotype. Additionally, unfractionated heparin (UFH) as well as low molecular weight heparin (LMWH) reduced tumor cell platelet interaction. Subsequently, attenuated platelet-derived mediator release resulted in reduced EMT marker protein and transcription factor expression by the cancer cells and decreased cell migration. These data suggest that heparin reduces platelet induced EMT program and prevents the formation of cancer cells with stem cell-like properties. This additional mechanism argues for the use of heparin in oncological applications.
topic heparin
platelet
tumor
epithelial-mesenchymal transition
EMT
cancer stem cells
enoxaparin
url http://www.mdpi.com/1420-3049/23/10/2690
work_keys_str_mv AT janmoritzponert unfractionatedandlowmolecularweightheparinreduceplateletinducedepithelialmesenchymaltransitioninpancreaticandprostatecancercells
AT lukasmariagockel unfractionatedandlowmolecularweightheparinreduceplateletinducedepithelialmesenchymaltransitioninpancreaticandprostatecancercells
AT svenjahenze unfractionatedandlowmolecularweightheparinreduceplateletinducedepithelialmesenchymaltransitioninpancreaticandprostatecancercells
AT martinschlesinger unfractionatedandlowmolecularweightheparinreduceplateletinducedepithelialmesenchymaltransitioninpancreaticandprostatecancercells
_version_ 1716762749382426624